NEW YORK (GenomeWeb News) — Clinical Data’s PGxHealth division will work with clinical researchers at George Washington University to study the effectiveness of using genomic testing to guide dosing decisions for the widely used anticoagulant warfarin, the company said yesterday.
 
The studies will use Clinical Data’s PGxPredict:Warfarin in a trial involving 80 post-surgical GWU patients to “evaluate the potential clinical, safety, and treatment-time benefits of using the genetic test to determine optimal warfarin dosing.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.